Loading…
Rein Therapeutics Inc. is projected to rise to $0.7651 by 2027, a +4% move from its current price of $0.7374. RNTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.7128 | $0.738 | $0.7642 | +0.08% |
| Aug 6 | $0.7031 | $0.7386 | $0.7759 | +0.17% |
| Aug 7 | $0.696 | $0.7392 | $0.7852 | +0.25% |
| Aug 8 | $0.6901 | $0.7399 | $0.7932 | +0.33% |
| Aug 9 | $0.685 | $0.7405 | $0.8004 | +0.42% |
| Aug 10 | $0.6805 | $0.7411 | $0.8071 | +0.50% |
| Aug 11 | $0.6765 | $0.7417 | $0.8133 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6765 | $0.7417 | $0.8133 | +0.59% |
| Week 2 | $0.6549 | $0.7461 | $0.8499 | +1.17% |
| Week 3 | $0.6398 | $0.7504 | $0.8802 | +1.77% |
| Week 4 | $0.6278 | $0.7548 | $0.9075 | +2.36% |
| Week 5 | $0.6179 | $0.7592 | $0.9329 | +2.96% |
| Week 6 | $0.6094 | $0.7637 | $0.957 | +3.56% |
| Week 7 | $0.602 | $0.7682 | $0.9801 | +4.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rein Therapeutics Inc. is a biopharmaceutical company that focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. Its lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Rein Therapeutics Inc. (RNTX) is currently trading with a price of $0.7374 and a market capitalization of $63.08M, holding a rank of 4385. The stock’s price outlook shows potential upside over the coming years, with a 2026 average price of $0.7374 and a 2050 average price of $3.31, alongside a maximum forecast of $6.74.
Forecasts indicate a path from a near-term neutral stance to longer-term bullish momentum, with annualized upside peaking in the 2040s and 2050s. These figures imply meaningful appreciation from the current level, though they are not guarantees and must be weighed against inherent risks.
A major floor 27.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 41.0% above — a clean break opens room to run.
A major ceiling 154.9% above — clearing it would confirm fresh momentum.
Key RNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7654 | Sell | $0.7664 | Sell |
| MA 10 | $0.7997 | Sell | $0.7986 | Sell |
| MA 20 | $0.8739 | Sell | $0.8492 | Sell |
| MA 50 | $0.9427 | Sell | $0.9545 | Sell |
| MA 100 | $1.15 | Sell | $1.07 | Sell |
| MA 200 | $1.23 | Sell | $1.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.67 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -115.94 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -22.09 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.75 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 18.19 | Buy |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.74 | Sell |
| ADX (14) | 22.36 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is bearish, with RSI(14) at 30. The price is below the SMA50 of $0.9427 and below the SMA200 of $1.23, indicating soft short-term momentum. Support is at $0.737 and resistance at $1.04, suggesting a tight trading range near the current price.
The 30-day range spans from a low of $0.5862 to a high of $0.9276, and the stock exhibits high volatility (annualized 70%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.737 | $0.7374 | $1.01 | 0% | Neutral | |
| $0.5951 | $0.7651 | $1.05 | +4% | Neutral | |
| $0.709 | $0.9461 | $1.36 | +28% | Bullish | |
| $0.8201 | $1.13 | $1.68 | +53% | Bullish | |
| $0.7694 | $1.09 | $1.67 | +48% | Bullish | |
| $0.7389 | $1.07 | $1.69 | +45% | Bullish | |
| $0.7183 | $1.07 | $1.72 | +45% | Bullish | |
| $0.7305 | $1.11 | $1.82 | +50% | Bullish | |
| $0.8109 | $1.26 | $2.11 | +71% | Bullish | |
| $0.9052 | $1.43 | $2.44 | +94% | Bullish | |
| $0.9275 | $1.61 | $2.96 | +119% | Bullish | |
| $1.61 | $3.31 | $6.73 | +348% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.737 | $0.7374 | $0.9253 | +0.00% |
| September 2026 | $0.6765 | $0.8064 | $0.9928 | +9.36% |
| October 2026 | $0.6616 | $0.7957 | $0.9929 | -1.34% |
| November 2026 | $0.6396 | $0.7748 | $0.9774 | -2.63% |
| December 2026 | $0.6513 | $0.7942 | $1.01 | +2.51% |
Click any year to see its month-by-month RNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RNTX could reach as high as $1.01, with a base case around $0.7374 and support toward $0.737 — roughly 0% from $0.7374. A consolidation phase looks the most probable path here.
Expect RNTX to range from $0.5951 to $1.05 through 2027. The $0.7651 average target implies a +4% move from current prices. That is up +4% on the projected 2026 average. Price action looks broadly range-bound.
The RNTX price prediction for 2028 points to an average of $0.9461 (low $0.709, high $1.36) — a potential gain of +28% on today's $0.7374. Buyers look set to stay in control over this stretch.
In 2029, RNTX is projected to trade between $0.8201 and $1.68, averaging $1.13 — a potential gain of +53% from today's $0.7374. That is up +19% on the projected 2028 average. Momentum favours further upside here.
Rein Therapeutics Inc.'s 2030 outlook centres on $1.09, within a $0.7694 to $1.67 range. That is -4% versus the projected 2029 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RNTX could reach as high as $1.69, with a base case around $1.07 and support toward $0.7389 — roughly +45% from $0.7374. Momentum favours further upside here.
Expect RNTX to range from $0.7183 to $1.72 through 2032. The $1.07 average target implies a +45% move from current prices. That is 0% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The RNTX price prediction for 2033 points to an average of $1.11 (low $0.7305, high $1.82) — a potential gain of +50% on today's $0.7374. Momentum favours further upside here.
In 2034, RNTX is projected to trade between $0.8109 and $2.11, averaging $1.26 — a potential gain of +71% from today's $0.7374. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Rein Therapeutics Inc.'s 2035 outlook centres on $1.43, within a $0.9052 to $2.44 range. That is up +14% on the projected 2034 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2040, RNTX could reach as high as $2.96, with a base case around $1.61 and support toward $0.9275 — roughly +119% from $0.7374. Buyers look set to stay in control over this stretch.
Expect RNTX to range from $1.61 to $6.73 through 2050. The $3.31 average target implies a +348% move from current prices. That is up +105% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RNTX today (≈ 1,356.116084 RNTX) could be worth
$4,482.45
+$3,482.45 (+348%) by 2050 · US Dollar
Based on the average projected RNTX price of $3.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNTXwould be worth at today's price.
$1,000 invested in RNTX on Jul 31, 2025 (≈ 858.369127 RNTX) would be worth
$632.96
-$367.04 (-36.7%) today · 0.63× · US Dollar
Based on a RNTX entry price of $1.16 vs. today's $0.7374.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.791 | $932.24 | -6.8% |
| 1 month ago | $0.978 | $753.99 | -24.6% |
| 3 months ago | $1.03 | $715.92 | -28.4% |
| 6 months ago | $1.29 | $571.63 | -42.8% |
| 1 year ago | $1.16 | $632.96 | -36.7% |
| All time (5.0y) ago | $19.62 | $37.58 | -96.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNTX forecast.
Our base-case forecast reaches $1.50 around 2040.
Implied market cap at $1.50: $128.31M
The multi-year forecast shows a bullish trajectory beginning in 2028, with the 2028 average price at $0.9466 and the 2029 average at $1.13, rising above $1.00 in subsequent years. The 2030 average is $1.09 and the 2031–2032 averages are $1.07, continuing a gradual climb toward later years. By 2040, the average price is projected to be $1.61 with a max of $2.96 and an ROI of 119%.
By 2050, the average price is forecast at $3.31 with a max of $6.74 and an ROI of 348.5%, accompanied by a bullish sentiment. Earlier years show neutral sentiment (2026 average $0.7374, 2027 average $0.7646) before the uplift. These projections reflect potential upside across the horizon, but they are estimates and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
2030 forecast: min $0.7681, avg $1.09, max $1.67; ROI 47.4%; sentiment BULLISH.
The forecast shows a bullish trajectory from 2028 onward, with 2028 avg $0.9466, 2040 avg $1.61, and 2050 avg $3.31; ROI reaches 119% by 2040 and 348.5% by 2050. However, these are estimates and carry risk.
Yes. The forecast max reaches $2.11 by 2034 and $2.45 by 2035, with a later max of $6.74 by 2050 (and a 2040 max of $2.96). These are indicative, not guarantees.
Current price is $0.7374. Market capitalization is $63.08M and the rank is 4385.
The 2050 forecast shows an average price of $3.31, a maximum of $6.74, a minimum of $1.61, and an ROI of 348.5%, with a bullish sentiment.
Rein Therapeutics Inc. Community Discussion
0Share your Rein Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.